Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis

Kim, Jin Su; Park, Su Cheol

doi:2016.16.2.82

J Liver Cancer > Volume 16(2); 2016 > Article

Review Article

Journal of Liver Cancer 2016;16(2):82-85.
DOI: https://doi.org/10.17998/jlc.16.2.82 Published online September 30, 2016.

Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis

Jin Su Kim, Su Cheol Park

Department of Internal Medicine, Korea Cancer Center Hospital, Korean Institute of Radiological and Medical Sciences, Seoul, Korea

Correspondence: Su Cheol Park,
Email: hepapark@kcch.re.kr

Abstract

Transarterial chemoembolization (TACE) has been widely performed as a treatment for unresectable hepatocellular carcinoma (HCC). Recently extrahepatic metastasis (EHM) of HCC is increasing due to improvement of survival. Sorafenib has been generally accepted as a standard treatment in advanced HCC. However, many HCC patients with EHM are treated with TACE in real-world clinical practice because sorafenib has modest efficacy and the main cause of death in the patients with EHM is hepatic failure. In this review, the usefulness of TACE for the patients with HCC and EHM will be discussed.

Key Words: Hepatocellular carcinoma; Extrahepatic metastasis; Transarterial chemoembolization

NULL